Thr92
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr92  -  PAH (human)

Site Information
KRsLPALtNIIKILR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 23128966

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
leukemia ( 2 ) , acute myelogenous leukemia ( 2 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 1 , 2 ) , acute megakaryoblastic leukemia (M7) ( 1 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 1 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 1 ) , acute myeloblastic leukemia, without maturation (M1) ( 1 ) , B cell lymphoma ( 1 ) , non-Hodgkin's lymphoma ( 1 ) , pancreatic cancer ( 3 ) , pancreatic carcinoma ( 3 ) , multiple myeloma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
JAK_inhibitor_I ( 2 ) , MEK_inhibitor_I ( 2 ) , PI-103 ( 2 )

References 

1

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

2

Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66
22547687   Curated Info

3

Tucker M (2009) CST Curation Set: 6669; Year: 2009; Biosample/Treatment: tissue, pancreas/untreated; Disease: pancreatic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info